Combination therapy in A549 cells

Nuclear Medicine and Biology

Volumn 37, Issue 3, 2010, Pages 317-326

  Yuan, Menghui ^a   Wang, Jing ^a   Deng, Jinglan ^a   Wang, Zhe ^a   Yang, Weidong ^a   Li, Guoquan ^a   Ren, Bingxiu ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

A549; Cytosine deaminase; Lung cancer; Receptor mediated radionuclide imaging; Somatostatin receptor; Suicide gene

Indexed keywords

CYTOSINE DEAMINASE; FLUOROURACIL; IODINE 131; SOMATOSTATIN RECEPTOR 2; TECHNETIUM 99M; VAPREOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; RADIOISOTOPE DISTRIBUTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FLUCYTOSINE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIOPHARMACEUTICALS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 77950297538     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.11.009     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56(2):106-130.
3. Stackhouse M.A., Buchsbaum D.J., Kancharla S.R., Grizzle W.E., Grimes C., Laffoon K., et al. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. Cancer Gene Ther 1999, 6(3):209-219.
4. Buchsbaum D.J. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Semin Nucl Med 2004, 34(1):32-46.
5. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003, 20(3):255-264.
6. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20(3):157-198.
7. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor imaging. Semin Nucl Med 2002, 32(2):84-91.
8. Woltering E.A. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 2003, 18(4):601-609.
9. Wang M., Caruano A.L., Lewis M.R., Meyer L.A., VanderWaal R.P., Anderson C.J. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 2003, 63(20):6864-6869.
10. 99mTc depreotide. Semin Nucl Med 2002, 32(2):92-96.
11. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133(2):647-658.
12. Thakur M., Kolan H., Rifat S., et al. Vapreotide labeled with Tc for imaging tumours: preparation and preliminary evaluation. Int J Oncol 1996, 9:445-451.
13. Mather S.J., Ward B.G. High efficiency iodination of monoclonal antibodies for radiotherapy. J Nucl Med 1987, 28(6):1034-1036.
14. 11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009, 69(3):873-878.
15. Shao W., Zhao S., Liu Z., Zhang J., Ma S., Sato J.D., Zhang P., Tong M., Han J., Wang Y., et al. Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun 2006, 349(2):816-824.
16. Charland S., Boucher M.J., Houde M., Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001, 142(1):121-128.
17. Mizuguchi H., Xu Z., Ishii-Watabe A., Uchida E., Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000, 1(4):376-382.
18. Goldenberg D.M., DeLand F., Kim E., Bennett S., Primus F.J., van Nagell J.R., et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978, 298(25):1384-1386.
19. Reubi J.C., Schaer J.C., Waser B., Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994, 54(13):3455-3459.
20. Reubi J.C., Waser B., Schaer J.C., Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995, 80(9):2806-2814.
21. Halmos G., Schally A.V., Sun B., Davis R., Bostwick D.G., Plonowski A. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000, 85(7):2564-2571.
22. Giannetti N., Enjalbert A., Krantic S. Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation. J Cell Biochem 2000, 78(4):666-673.
23. Lachowicz-Ochedalska A., Rebas E., Kunert-Radek J., Winczyk K., Pawlikowski M. Effects of somatostatin and its analogues on tyrosine kinase activity in rodent tumors. Biol Signals Recept 2000, 9(5):255-259.
24. Pollak M.N., Schally A.V. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998, 217(2):143-152.
25. Zalatnai A., Szegedi Z., Bocsi J. Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide). Anticancer Res 2000, 20(3A):1663-1666.
26. Lal S., Lauer U.M., Niethammer D., Beck J.F., Schlegel P.G. Suicide genes: past, present and future perspectives. Immunol Today 2000, 21(1):48-54.
27. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleosides. J Natl Cancer Inst 1996, 88(17):1193-1203.
28. Huber B.E., Austin E.A., Richards C.A., Davis S.T., Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994, 91(17):8302-8306.
29. Warmann S.W., Armeanu S., Heigoldt H., Ruck P., Vonthein R., Heitmann H., Seitz G., Lemken M.L., Bitzer M., Fuchs J., et al. Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr Blood Cancer 2009, 53(2):145-151.
30. Lv S.Q., Zhang K.B., Zhang E.E., Gao F.Y., Yin C.L., Huang C.J., et al. Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Med Sci Monit 2009, 15(1):BR13-BR20.
31. Wu D.H., Liu L., Chen L.H. Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells. World J Gastroenterol 2005, 11(20):3051-3055.
32. Pandha H.S., Cook D., Greenhalgh R., Dalgleish A. Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy. BJU Int 2005, 95(9):1336-1343.